Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
暂无分享,去创建一个
Huibi Xu | Xiangliang Yang | Huibi Xu | Xiangliang Yang | Huabing Chen | Dongsheng Mou | Jiangling Wan | Huabing Chen | Dongsheng Mou | Jiangling Wan
[1] L. Froyen,et al. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[2] Wei Yang,et al. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. , 2008, Molecular pharmaceutics.
[3] C. Branford-White,et al. Third generation solid dispersions of ferulic acid in electrospun composite nanofibers. , 2010, International journal of pharmaceutics.
[4] Rainer H Müller,et al. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18. , 2010, International journal of pharmaceutics.
[5] Alex Avdeef,et al. Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules. , 2004, Chemical & pharmaceutical bulletin.
[6] A. Müllertz,et al. Adsorption of pharmaceutical excipients onto microcrystals of siramesine hydrochloride: effects on physicochemical properties. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[7] Huibi Xu,et al. A facile nanoaggregation strategy for oral delivery of hydrophobic drugs by utilizing acid–base neutralization reactions , 2008, Nanotechnology.
[8] Carmen Popescu,et al. Conversion of Nanosuspensions into Dry Powders by Spray Drying: A Case Study , 2008, Pharmaceutical Research.
[9] Huibi Xu,et al. Oleanolic acid nanosuspensions: preparation, in‐vitro characterization and enhanced hepatoprotective effect , 2005, The Journal of pharmacy and pharmacology.
[10] Barrett E. Rabinow,et al. Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.
[11] Hak-Kim Chan,et al. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. , 2004, International journal of pharmaceutics.
[12] Christel A. S. Bergström,et al. Accuracy of calculated pH-dependent aqueous drug solubility. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[13] Blair K. Brettmann,et al. Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. , 2007, Molecular pharmaceutics.
[14] Ranjita Shegokar,et al. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. , 2010, International journal of pharmaceutics.
[15] M. Mazzotti,et al. Miconazole nanosuspensions: Influence of formulation variables on particle size reduction and physical stability. , 2010, International journal of pharmaceutics.
[16] Chong-K. Kim,et al. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[17] J. Peeters,et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. , 2002, Journal of pharmaceutical sciences.
[18] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[19] H. Kranz,et al. Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] J. Ayres,et al. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. , 2001, International journal of pharmaceutics.
[21] Filippos Kesisoglou,et al. Nanosizing--oral formulation development and biopharmaceutical evaluation. , 2007, Advanced drug delivery reviews.
[22] Jonathan Brown,et al. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches. , 2009, International journal of pharmaceutics.
[23] M. Odomi,et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[24] Siling Wang,et al. Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. , 2007, International journal of pharmaceutics.
[25] Patrick Augustijns,et al. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[26] G. Ennas,et al. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. , 2009, International journal of pharmaceutics.
[27] J. Rollinger,et al. Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. , 2000, Journal of pharmaceutical sciences.